Synbio International Inc. Expands Its Board of Directors and Strengthens Clinical Leadership

On October 22, 2025, Synbio International Inc. appointed Dr. Nick Vatakis, MD as Medical Director and added him to its Board of Directors1.

Dr. Vatakis brings nearly 30 years of clinical and research experience, including serving as principal investigator on more than 200 clinical trials and as a founder and CMO of a clinical research organization1.

Dr. Vatakis will oversee the design and execution of Synbio’s upcoming feasibility trial for its AI-driven facial analysis depression screening software, upholding ethical, medical, and scientific standards1.

His appointment is intended to enhance Synbio’s clinical rigor, regulatory credibility, and commercialization efforts for its medical technology1.

On October 2, 2025, Synbio also appointed Ms. Desiree Cain, CPA, MBA, as Chief Financial Officer and Member of the Board of Directors57.

Ms. Cain has over 25 years of experience in corporate finance, accounting, and strategic growth management, and will lead financial operations as well as the development of governance and risk management frameworks for the company57.

These appointments reflect Synbio's ongoing efforts to strengthen both clinical and corporate governance leadership as the company moves toward clinical validation and business growth15.

Sources:

1. https://www.stocktitan.net/news/SYIN/synbio-international-inc-expands-its-board-of-directors-and-51yvgxgwto4g.html

5. https://www.marketscreener.com/news/synbio-international-inc-appoints-desiree-cain-as-member-of-the-board-of-director-effective-octob-ce7d5bded08ff622

7. https://www.globenewswire.com/de/news-release/2025/10/02/3160497/0/en/Synbio-International-Inc-Expands-Board-and-Strengthens-Leadership-with-Appointment-of-Chief-Financial-Officer-Ms-Desiree-Cain-CPA-MBA.html